Volume 1

Issue 1

Article 20

Management of Non metastatic Colo-Rectal Cancers During the COVID-19
Pandemic: Viewpoint
Fadila Kouhen
Department of Radiotherapy, International University Hospital Sheikh Khalifa. Mohammed VI University of Health
Sciences (UM6SS), Casablanca, Morocco, fadila10m@hotmail.com

Meriem Chihabeddine
Department of Radiotherapy, International University Hospital Sheikh Khalifa. Mohammed VI University of Health
Sciences (UM6SS), Casablanca, Morocco

Mohammed Afif
Department of Radiotherapy, National Institute of Oncology. Mohammed V University In Rabat, Morocco

Nadia Errafiy
National Reference Laboratory (LNR). Mohammed VI University of Health Sciences (UM6SS). Casablanca, Morocco

Follow this and additional works at: https://journal.um6ss.ma/health-sciences
Part of the Medicine and Health Sciences Commons

Recommended Citation
Kouhen, Fadila; Chihabeddine, Meriem; Afif, Mohammed; and Errafiy, Nadia (2020) "Management of Non metastatic
Colo-Rectal Cancers During the COVID-19 Pandemic: Viewpoint," Health Sciences: Vol. 1: Iss. 1, Article 20.
Available at: https://doi.org/10.15342/hs.2020.280
This Viewpoint is brought to you for free and open access by Health Sciences. It has been accepted for inclusion in Health
Sciences by an authorized editor of Health Sciences.

HEALTH SCIENCES
2020, Volume 1, ID 280
DOI: 10.15342/hs.2020.280

VIEWPOINT

Management of Non Metastatic Colo-Rectal Cancers
during the COVID-19 Pandemic: Viewpoint
Fadila Kouhen a

, Meriem Chihabeddine a , Mohammed Afif b , Nadia Errafiy c

ᵃ Department of Radiotherapy, International University Hospital Sheikh Khalifa. Mohammed VI University of Health Sciences (UM6SS).
Casablanca, Morocco.
b Department of Radiotherapy, National Institute of Oncology. Mohammed V University In Rabat, Morocco.
c National Reference Laboratory (LNR). Mohammed VI University of Health Sciences (UM6SS). Casablanca, Morocco.

ABSTRACT
Recently, an ongoing outbreak of pneumonia caused by a novel coronavirus, known as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has spread throughout Morocco and the rest of the world with more than 4.5 million confirmed
cases and 300,000 deaths in 188 countries.
As oncologists, it’s difficult to choose between delaying oncological treatment which increases the risk of progression and
death from the disease and increasing the risk of contamination by Covid 19 Virus for patients who are very vulnerable.
Colorectal cancer is a real public health problem, it represents the third most commonly diagnosed cancer in males and the
second in female.
The purpose of the present work is to review the recommendations from the international evidence-based guideline for
managing patients with Non metastatic colo-rectal cancers during the COVID- 19 crisis.
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Recently, an ongoing outbreak of pneumonia caused by a
novel coronavirus, known as severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spread
throughout Morocco and the rest of the world with more
than 4.5 million confirmed cases and 300,000 deaths in
188 countries.
Cancer patients are considered as a highly vulnerable
group in the current COVID-19 pandemic. According to a
recently published Chinese cohort, patients with cancer
had a higher risk of developing severe events defined by
admission to the intensive care unit (ICU), mechanical
ventilation, or death compared with patients without
cancer (39 % vs 8%, p = 0·0003) [1].
As oncologists, it’s difficult to choose between delaying
oncological treatment which increases the risk of
progression and death from the disease and increasing the
risk of contamination by Covid 19 Virus for patients who
are very vulnerable. However, the risks related to COVID19 should be balanced against tumour control and
discussed on a case-by-case basis.

Health Sci.2020;1:2p

Colorectal cancer is a real public health problem, it
represents the third most commonly diagnosed cancer in
males and the second in female, with an estimated 1,4
million cases and 693,900 deaths occurring in 2012 [2].
According to the Cancer Registry of Rabat, colorectal
cancer represents the first gastro-intestinal cancer, and the
fourth most common cancer, with an incidence of 8,4/100
000 habitants in 2008 with a significant increase in
incidence these last years due to considerable progress in
the detection, diagnosis and treatment of cancer [3].
In rectal cancer, an international panel of cancer experts
issued an international expert consensus statement in
the Radiotherapy & Oncology journal regarding treatment
options for patients with rectal cancer during the
coronavirus disease 2019 (COVID-19) pandemic [4].
For early stage, total mesorectal excision (TME) alone
without pre-operative radiotherapy is recommended.
For locally advanced (T2N+ or T3-4/Nany) operable rectal
patients, we should strongly consider using short-course
pelvic radiotherapy (5Gy x 5 fractions) during this
pandemic with comparable outcomes for local recurrence,
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disease free survival, overall survival and late toxicity
compared to the usual 5 weeks of radiotherapy coupled
with chemotherapy [5,6].
More recently, timing for rectal cancer surgery after
neoadjuvant chemoradiotherapy has been studied as an
independent variable that may influence perioperative
complications, risk for local recurrence , and overall
survival .
Recent evidence indicates that surgery, which usually
takes place one week after radiotherapy, can be safely
postponed for 6 to 8 weeks or more [7,8].
This approach avoids the need for chemotherapy, which
can compromise the immune system leaving patients
vulnerable to infection.
The Stockholm III trial randomly assigned patients to 5 ×
5 Gy radiotherapy and surgery within 1 week (short-course
radiotherapy), 5 × 5 Gy radiotherapy and surgery after 4–
8 weeks (short-course radiotherapy with delay), or 25 × 2
Gy radiotherapy and surgery after 4–8 weeks (longcourse
radiotherapy with delay).
the trial showed no difference in local recurrence rates,
distant metastases, recurrence-free or overall survival
between the three arms with any postoperative morbidity
(53% vs. 41%, p ¼ .001) and surgical morbidity (36% vs.
28%, p ¼ .03) were higher in the short-course RT with
immediate surgery group compared to the delayed surgery
groups. Reoperations did not differ between groups (15%
vs. 14%).
The National Comprehensive Cancer Network (NCCN)
has published guidelines for the Cancer Care Community
to keep patients with cancer, care providers and staff safe
during the COVID-19 Pandemic.
They recommend consider several months delay of routine
endoscopic, radiologic and biologic surveillance
monitoring until the pandemic has resolved and the using
of telehealth to evaluate patient and assure clinical stability
especially in older patients or those with other
comorbidities.
For colon cancer, Timing of surgery has been shown to
affect outcomes in many forms of cancer, including colon
cancer.
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The ideal time of resection has been estimated to be
between 3 and 6 weeks from diagnosis,6 which is unlikely
to be achieved during COVID-19 outbreak [9].
The experts strongly recommend a course of neoadjuvant
capecitabine or CapeOx chemotherapy.for patients with
newly diagnosed stage 2–3 cancer who are unable to have
surgery due to COVID-19 constraints.
For adjuvant therapy, the American Society of Clinical
Oncology (ASCO) Guideline recommends recently, based
on the results from trials of 3- and 6-month oxaliplatincontaining chemotherapy leucovorin, fluorouracil, and
oxaliplatin (FOLFOX) or capecitabine and oxaliplatin
(CAPOX), Shorter-Course Adjuvant Chemotherapy for
low risk patients with Stage III Colon Cancer.
The guideline defines low-risk patients as having either
T1, T2, or T3, and N1 stage tumors and high-risk patients
as having T4 and/or N2 stage tumors
As stated, treatment for colorectal cancer is not elective
and therefore we must help our patients to receive
optimized treatment for their colorectal cancer, while at
the same time minimizing their individual risk of infection
and maintain optimal clinical outcomes, especially in the
curative setting.
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